劉益昇醫師詳細介紹

血液病診斷與治療，各項癌症內科治療

國防醫學院醫學系學士

中國醫藥大學老化醫學博士學程研究所博士班

國軍臺中總醫院住院醫師

左營海軍新兵訓練中心醫官

三軍總醫院內科部血液腫瘤科進修醫師

國軍臺中總醫院急診專責醫師

國軍臺中總醫院內科部血液腫瘤科主治醫師

國軍高雄總醫院內科部血液腫瘤科主治醫師

國防醫學院助理教授

Liu YS, Wang NC, Yeh RH, Kao WY. Disseminated fusarium infection in a patient with acute lymphoblastic leukemia: A case report and review of the literature. Oncol Lett. 2014;7(2):334-336.

Liu YS, Tsai YL, Yeh YL, Chung LC, Wen SY, Kuo CH, Lin YM, Padma VV, Kumar VB, Hung CY. Cell cycle regulation in the estrogen receptor beta (ESR-2)-overexpressing Hep3B hepatocellular carcinoma cell line. Chin J Physiol. 2015;58(2):134-40.

Yi-Sheng Liu, Yu-Chun Chang, Wei-Wen Kuo, Ming-Cheng Chen, Hsi-Hsien Hsu, Chuan-Chou Tu, Yu-Lan Yeh, Vijaya Padma Viswanadha, Po-Hsiang Liao, Chih-Yang Huang. Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress eIF2 Activation to Enhance Fisetin-induced Chemosensitivity in HDAC Inhibitor-resistant Hepatocellular Carcinoma Cells. Cancers 2019, 11, 918; doi:10.3390

Yi-Sheng Liu, Yu-Chun Chang, Wei-Wen Kuo, Ming-Cheng Chen, Tso-Fu Wang, Tung-Sheng Chen, Yueh-Min Lin, Chi-Cheng Li, Po-Hsiang Liao, Chih-Yang Huang. Calreticulin nuclear translocalization alleviates CaM/CaMKII/CREB signaling pathway to enhance chemosensitivity in HDAC inhibitor resistant hepatocellular carcinoma cells. AGING 2022, 14(12):5097-5115.